Ryvu Therapeutics to Present Data from Its Oncology Programs at the 2022 AACR Annual Meeting

KRAKOW, Poland, March 8, 2022 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focused on novel small molecule therapies that target emerging targets in oncology, today announced that data from its oncology programs will be presented at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, which will take place April 8-13 in New OrleansWE

Posters to be presented at the conference will include data from RVU120, a CDK8/CDK19 inhibitor program targeting hematological and solid tumors, and data from a cooperative PRMT5 inhibitor program with MTA.

“We are excited to share recent preclinical breast cancer data from our most advanced oncology program, RVU120. This selective CDK8/CDK19 inhibitor is currently in the phase 1b clinical development for the treatment of acute myeloid leukemia or high-risk myelodysplastic syndromes, as well as in patients with metastatic or advanced solid tumors, and has already provided promising data,” said Krzysztof Brzózka, Chief Scientific Officer of Ryvu Therapeutics . “We have also made rapid progress in our cooperative MTA program on PRMT5 inhibitors, and we look forward to sharing these updates with the scientific community,” adds Dr. Brzózka.

Abstract/poster details:

Title: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and live
Abstract number: 2647
RVU120 is a selective, low-nM inhibitor of CDK8/CDK19, currently being tested in a first-in-man Phase Ib clinical trial in patients with metastatic or advanced solid tumors progressing from previous treatment lines (ClinicalTrials.gov: NCT05052255). Studies on a panel of cell lines representing various breast cancer subtypes revealed that TNBC cells were highly sensitive to RVU120. Molecular profiling of responder cells indicated high enrichment for the mesenchymal stem cell subtype. Single-Agent Efficacy of RVU120 Confirmed in Subcutaneous TNBC Xenograft Models live at well tolerated doses. Taken together, these studies support the further development of RVU120 in TNBC patients.
Session title: New targets and routes
Session date and time: Tuesday, April 12, 2022 9:00 a.m. – 12:30 p.m.
Location: Section 24 Poster

Title: Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
Abstract number: 1117
Targeting PRMT5 in MTAP-suppressed tumors in a synthetic lethal approach represents a promising antitumor strategy for many tumor types. Ryvu has identified a series of MTA-cooperative PRMT5 inhibitors with good drug-like physicochemical properties and blocking methyltransferase activity with nanomolar IC50 values. Ryvu compounds selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which is strongly correlated with inhibition of symmetrical PRMT5-dependent protein (SDMA) demethylation in these cells. Taken together, these studies warrant further optimization of chemical series towards a clinical candidate.
Session title: Drug targets
Session date and time: Monday, April 11, 2022 1:30 p.m. – 5:00 p.m.
Location: Section 23 Poster

Title: Ongoing trials – RVU120 SOL-021: an open-label phase I/II monotherapy trial of RVU120 (SEL120) in patients with metastatic or advanced relapsed/refractory solid tumors
Abstract number: 8023
SOL-021 is a Phase I/II clinical trial of RVU120 in patients with metastatic or advanced solid tumors, who have exhausted available therapies, currently underway in Poland and Spain (NCT05052255). The study is designed in 2 parts: Part 1 follows a 3+3 dose escalation design, and the primary objectives are to characterize the safety and tolerability of RVU120 as a single agent in patients with different types of tumors and to determine the RP2D. Part 2 will mainly explore the anti-tumor activity of RVU120 as a single agent in different patient populations. From a data cut of February 11, 20225 patients were included in part 1 of the study and no DLT was observed.
This summary of ongoing trials is published in cooperation with the Center for Early Clinical Trials and Department of Oncology and Radiation Therapy, Gdansk Medical University, Poland; Early Drug Development Unit (UITM) Vall d’Hebron Oncology Institute (VHIO), Vall d’Hebron University Hospital, Barcelona, ​​Spain; Dep. of Internal Medicine III, Univ. Clinic, Bonn, Germany and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Session title: Phase II trials underway
Session date and time: Monday, April 11, 2022 21:00 – 12:30
Location: Section 34 poster

About the AACR Annual Meeting

The AACR Annual Meeting program covers the latest findings across the spectrum of cancer research, from population and prevention sciences to cancer biology, translational and clinical studies; to survival and advocacy – and highlights the work of the best minds in research and medicine from institutions around the world. Additional information is available on the AACR conference website http://www.aacr.org.

About Ryvu Therapeutics

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that target emerging targets in oncology. The internally discovered pipeline candidates utilize a variety of therapeutic mechanisms driven by new insights into cancer biology, including small molecule kinase-directed, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are: RVU120 – a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of metastatic or advanced solid tumors r/r and SEL24 (MEN1703) – dual PIM/FLT3 kinase inhibitor licensed to the Menarini group, currently in phase II clinical studies in myeloid leukemia acute.

The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the main market of the Warsaw Stock Exchange and is part of the sWIG80 index. For more information, please visit www.ryvu.com.

SOURCE Ryvu Therapeutics

Comments are closed.